Cyfuse Biomedical K.K. Cash Flow Statement

Financials in millions JPY. Fiscal year is January - December.

Millions JPY. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Net Income	-869	-586	-471	-	-
Depreciation & Amortization	38	40	63	-	-
Other Operating Activities	43	124	5	-	-
Change in Accounts Receivable	-3	-3	44	-	-
Change in Inventory	-9	-5	21	-	-
Change in Accounts Payable	22	-20	-3	-	-
Change in Other Net Operating Assets	18	-112	-62	-	-
Operating Cash Flow	-760	-562	-403	-	-
Capital Expenditures	-8	-19	-228	-	-
Investment in Securities	-	-	-200	-	-
Other Investing Activities	-	-	-2	-	-
Investing Cash Flow	-8	-19	-430	-	-
Short-Term Debt Issued	-	73	328	-	-
Long-Term Debt Issued	-	-	90	-	-
Total Debt Issued	-	73	418	-	-
Short-Term Debt Repaid	-51	-	-	-	-
Long-Term Debt Repaid	-18	-77	-82	-	-
Total Debt Repaid	-69	-77	-82	-	-
Net Debt Issued (Repaid)	-69	-4	336	-	-
Issuance of Common Stock	17	22	2,329	-	-
Other Financing Activities	-	-	-7	-	-
Financing Cash Flow	-52	18	2,658	-	-
Miscellaneous Cash Flow Adjustments	-1	-	-1	-	-
Net Cash Flow	-821	-563	1,824	-	-
Free Cash Flow	-768	-581	-631	-	-
Free Cash Flow Margin	-1422.22%	-952.46%	-168.72%	-	-
Free Cash Flow Per Share	-95.40	-74.37	-236.54	-	-
Cash Interest Paid	9	9	7	-	-
Cash Income Tax Paid	2	2	2	-	-
Levered Free Cash Flow	-585.25	-446.88	-458	-	-
Unlevered Free Cash Flow	-579	-440.63	-453.63	-	-
Change in Working Capital	28	-140	-	-	-

Source: S&P Global Market Intelligence. Standard template. Financial Sources.